WHAT THIS PAPER ADDS Long-term follow up of chimney and periscope grafts for the treatment of pararenal and thoraco-abdominal aortic aneurysm is presented. This approach using off the shelf devices has been increasingly reported in recent years and with good results even in emergent settings. This risk factor analysis showed that inadequate branch graft length and chimney and periscope use in small and diseased target arteries contribute to late failure of this technique.
INTRODUCTION
Endovascular treatment of pararenal abdominal aortic aneurysms (PAAAs) and/or thoraco-abdominal aortic aneurysms (TAAAs) is usually performed using fenestrated or branched stent grafts (B/FEVAR). 1 However, because of anatomical limitations, device non-availability, and time consuming customization, a significant number of patients are excluded from B/FEVAR. 2 To overcome these limitations, parallel graft techniques using a combination of off the shelf devices have been developed to fit most of such complex cases. 3 Unfortunately, until now data published on chimney and periscope grafts (CPGs) have been limited, especially with regard to long-term results. In order to add supportive data on the value of this technique, mid-and longer-term outcomes of over 4 years of CPGs used in a single center over an 8 year experience are reported. This series includes 100 consecutive patients treated by CPG techniques in an intention to treat protocol, with standardized implantation methods and follow up protocols.
METHODS AND PATIENTS
This was a single center retrospective analysis of prospectively gathered data from 100 patients deemed unsuitable for conventional surgery and treated from January 2008 to August 2013 with at least one renal or visceral chimney or periscope graft. A vascular board including a cardiovascular surgeon and interventional radiologist selected patients. Briefly, patients with low surgical risk (good anatomy for clamping and grafting; young with unrestricted organ function, especially normal heart, lung and renal function) were treated by open surgery. 4 Patients presenting high risk for conventional surgery were treated by hybrid repair techniques (approximately 70e80% of all open repairs), and patients at high surgical risk for open surgery and/or unfit for fenestrated endovascular devices were treated endovascularly with parallel graft techniques. During the study period most patients presenting with aortic aneurysms involving the visceral aorta were treated by the hybrid repair technique (20%) or completely endovascularly (50%). Overall, 10 custom made branched/fenestrated grafts were used. Conventional open surgery was performed in the remaining 30% of cases. This series included 69 PAAAs (no normal aorta between the origin of the aneurysm and the lowest renal artery) and 31 TAAAs. 5 Eight TAAAs extended to the aortic arch. Seventy-three (73%) patients were treated electively and 27 (27%) non-electively (12 ruptured cases). Demographics and comorbidities 5e8 are reported in Table 1 .
Investigational informed consent for the procedure and study was obtained from all patients. Clinical data were collected with the university hospital clinical information system (Dendrite, Dendrite Clinical Systems, Ltd, Henley-onThames, UK; KISIM 4.901, CISTEC AG, Zurich, Switzerland) and updated in February 2015. Earlier data with shorter follow up for some of these patients have been published previously. 3 
Standardized protocol
An aortic board reviewed all cases pre-operatively to assess CPG feasibility. Pre-operative thoraco-abdominal computed tomographic arteriography (CTA) was performed in all patients. CTA images were analyzed with the 3mensio software (3mensio Medical Imaging BV, Bilthoven, The Netherlands) to assess disease extent, and aortic and branch dimensions and angulations. The material necessary to construct the CPG(s) and implantation routes were based on patient specific anatomy ( Figs. 1 and 2) . A 2 cm long sealing zone in the normal vessel wall (diameter and endoluminal morphology) was required in the aorta and its branches. A shorter landing zone in aortic branches (<10 mm) required special deployment techniques (described below).
The aortic devices used are reported in Table 1 . Sizing was based on the following formula: mean aortic diameter at landing zone þ half the diameter of each CPG used. In patients <70 years, an additional 10% aorta oversizing was used to anticipate future natural aortic growth. In challenging anatomies, repositionable grafts were used for more precise deployment and possible repositioning. CPGs were mostly constructed using a Viabahn device (WL Gore & Associates, Flagstaff, AZ, USA). The length of the Viabahn was chosen to extend, at least one centimeter, the CPG beyond (above or below) the covered part of the aortic stent graft and to leave a 1e2 cm landing zone within the aortic branch. The Viabahn device diameter generally included 1 mm of oversizing. In a few cases, at the beginning of the experience or for CPG stenosis or in the few highly stenotic vessels, self expandable and/or balloon expandable bare stents were used in 12 branches (5%). Overall, 224 (mean 2.24; SD 0.93; range 1e4) aortic branches were treated with CPGs and a mean of 1.49 stent grafts/stents was used per CPG (range 1e4; SD 0.76) ( Table 2) .
Implantation technique
CPG procedures were performed under local (35 patients; 63 vessels) or general anesthesia (65 patients; 161 vessels). Lidocaine 1% diluted with 8.4% sodium bicarbonate was used for analgesia in remote access site preparation (cut down or percutaneous). Mainly for patient comfort, analgesic sedation was added to local anesthesia. Procedures were performed in a radiology angiography suite (Artiszeego; Siemens AG, Forchheim, Germany) or in a hybrid operating room (Philips Medical Systems, Inc., Shelton, CT, USA). A bolus of 5,000 units of heparin was injected before endovascular sheath introduction. Heparin was readministered to keep the activated clotting time value to >180 seconds or >250 seconds if supra-aortic access was used. Chimney grafts deliver antegrade flow and were generally introduced and deployed from the left axillary artery. On the other hand, periscope grafts deliver retrograde blood flow and were introduced transfemorally. Following cannulation and sheath placement in the renovisceral branch, the Viabahn was introduced into the target vessel, deployed, and molded with a 2 cm long angioplasty balloon to achieve good anchorage. Aortic stent grafts were deployed and pullback traction was applied to the CPG balloon(s), to orientate the CPG(s) parallel to the aortic axis. A simultaneous kissing ballooning completed the procedure. Selective angiography and pressure measurements inside any aortic and branch stent graft were performed to exclude relevant endoleak(s) and/or significant pressure gradient(s). Low flow Type Ia (gutters and leaks limited to proximal neck) endoleaks, 9 even in patients with aortic rupture and coagulation disorder, were tolerated. In the latter part of the experience (7 cases; 7%) the CPGs were relined primarily with Wallstents (Boston Scientific Corp., Marlborough, MA, USA) to improve visibility. 10 In 22 (22%) cases a visceral debranching of one or two branches preceded the CPGs.
Special techniques. In short reno-visceral artery landing zones ( 10 mm), the CPG was deployed after the aortic stent graft. The transfemoral lift technique was used to construct 23/224 (10%) reno-visceral chimneys in patients with a highly diseased aortic arch.
11 Twenty-three of 224 (10%) CPGs were constructed using the sandwich technique, by placing the CPG between two aortic stent grafts (12) , or a surgical graft and a stent graft (11) to reduce CPG length. 12 Thirteen (57%) sandwiches were constructed in the periscope configuration and 10 (43%) in the chimney configuration.
Peri-operative management
Post-operative quality controls. Duplex ultrasound (DUS) with kidney and liver resistance index measurements was performed immediately after the procedure. In ruptured cases, CTA was performed immediately after the CPGe EVAR procedure. In patients with severe chronic renal failure, contrast DUS and non-contrast CT were used during follow up.
Treatment of endoleaks or CPGs stenosis. High flow endoleaks I/III or relevant CPG stenoses were corrected immediately. Low flow endoleaks, 9 Type II endoleak and slight stenosis not associated with a significant pressure gradient were managed conservatively.
Management of blood pressure. After TAAA treatment, blood pressure was maintained between 120 and 150 mmHg for 6 weeks, to avoid spinal hypoperfusion. Patients developing neurological symptoms while hospitalized were treated with Mannitol 20%, a 50 mL bolus every 2e4 hours and transferred to the ICU for blood pressure (systolic pressure !140 mmHg; mean arterial pressure 70e 90 mmHg) and hematocrit (>30%) optimization. Cerebrospinal fluid drainage (CSFD) was not used peri-operatively and not even post-operatively in symptomatic patients because of its debatable preventive value and because of the serious concerns about inserting the CSFD catheter under heparinization.
Medications. Combined antiplatelet therapy (100 mg/day aspirin) and full therapeutic heparinization were administered during hospitalization. Before discharge, patients were switched to dual antiplatelet therapy or single antiplatelet therapy combined with an oral anticoagulant for at least 3 months. To reduce the risk of post-implantation systemic inflammatory syndrome, 13 vaso-plegic syndrome, 14, 15 and/or atrial fibrillation 16 and the consequent low cardiac output, 17 low dose steroids were administered orally for 5 days (prednisone 20 mg/day for 2 days, prednisone 10 mg/day for 2 days and prednisone 5 mg/day for 2 days).
Follow up
Follow up was 6 weeks, 3 months, 6 months, and annually thereafter; all patients were ambulatory. CTA, laboratory testing and clinical examination were performed. Basal CT and DUS were employed when CTA was contraindicated by impaired renal function. 18 
Study outcomes
Short term. The short-term outcomes were to calculate the immediate technical success rate (procedure completed as intended without high flow Type I/III endoleak and/or CPG occlusion), post-operative (30 day/in hospital) mortality and morbidity (including renal, respiratory, visceral, access and infection complications), ICU and hospital duration, CPG patency rates, and the presence of an endoleak at 30 days.
Mid-term
The mid-term outcomes were to calculate survival, CPG patency rates, endoleak rate, maximum aneurysm size and re-interventions during follow up. A significant aneurysm maximum transverse diameter (MAXTD) difference was defined as a variation of !5 mm on CTA.
CPG failure risk factor analysis
The following variables were analyzed: (a) diagnosis of PRAA versus TAAA; (b) elective versus non-elective treatment; (c) 1e2 CPG versus 3e4 CPG implantation; (d) CG versus PG versus CPG configuration, (e) renal versus visceral versus all treatment; (f) aortic stent graft fabric; (g) CPG collapse (>70% stenosis), and/or very short CPGs (<5 mm) versus no collapse or short CPG; and (h) target vessel atherosclerosis (stenosis >50%) or diameter < 4 mm versus nondiseased vessels, which were tested for the following late outcomes: (1) mortality at follow up; (2) aneurysm maximum diameter reduction; (3) CPG patency; (4) reinterventions.
Statistical analysis. Means (m), range (r) and standard deviation (SD) were reported for parametric data; absolute values and percentages for non-parametric data. Owing to the inclusion of exactly 100 patients, percentages were generally omitted when dealing with patient numbers. Differences between groups were assessed using the t test, and chi-square test. The risk factor multivariate analysis was conducted with multivariate analysis of variance (MAN-OVA). KaplaneMeier curves were used to estimate survival, primary, and secondary patency and freedom from reinterventions. Differences in curves were assessed with the Breslow test. Statistical significance was considered to be p < .05. For KaplaneMeier curves confidence interval (CI) and standard error exceeding 10% were reported. Statistical analysis was performed using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The immediate technical success rate was 99%, as all but one procedure could be completed as intended. In one patient a renal artery could not be preserved. The mean procedure time was 252 (SD 190) minutes. A significantly higher number of patients with multiple (>2) CPGs were performed under general anesthesia than under local anesthesia (2.47 vs. 1.8; p ¼ .01). Post-operative mortality occurred in two (2%) patients who developed multiple organ failure (1 rhabdomyolysis and 1 abdominal compartment syndrome after ruptured PAAA). Post-operative complications requiring re-interventions during the initial hospitalization included an axillary hematoma (2; 2%), bilateral lymphatic fistula in the groin (1; 1%), iliac limb occlusion (2; 2%), and mesenteric ischemia (1; 1%). Moreover, seven (7%) patients required CPG-related re-interventions early for CPG thrombosis (3) and/or endoleaks (4) ( Table 3) . Four subcapsular renal hematomas with no renal functional impairment were treated conservatively. 19 Neurological complications (spinal cord ischemia) occurred in three cases. These were successfully managed by pressure and hematocrit optimization and infusion of 50 mL of Mannitol 20% every 4 hours until the symptoms disappeared.
The overall experience with a median follow up of 28 (mean 29; range 0e65; SD 17) months including 59 patients followed > 2 years, 30 patients followed > 3 years and 16 patients followed > 4 years. Only one patient (1%) was lost during follow up. A 14% reduction in aneurysm maximum transverse diameter (CI 5.39e10.28; p < .001) was observed between the pre-operative (71.76 [median 65; range 38e185; SD 23] mm) and the last CTA (61.49 [median 56.5; range 30e162; SD 24] mm). There was a reduction of the maximal transverse diameter in 56 (56%) patients, no change in 40 (40%), and progression in four (4%). No stent graft migration was observed (Fig. 3) .
Post-operatively, 28 (28%) CPG related re-interventions (including the 7 early ones mentioned above) were performed at a mean interval of 11.45 (range 0e38; SD 26) months; 25/28 (89%) were performed endovascularly and three of 28 (11%) with open bypass procedures (Table 3) .
Of the 28 re-interventions, 15 (54%) were performed for endoleak related issues. At the latest follow up of all cases, a Type I/III endoleak was evident in 5% of cases. Out of the 23 Type I/III endoleaks noted post-operatively, 15 were treated (4 early and 11 late) and three sealed spontaneously. The remaining five Type I/III endoleaks were low flow. These remain under surveillance as long as the aneurysm diameter remains stable (Table 3 ). The estimated endoleak free survival after secondary procedures is shown in Fig. 4 .
Post-operatively, relevant CPG stenosis or thrombosis requiring re-intervention was detected in 13 of 224 (5.8%) branches. The mean interval to re-intervention was 2.6 (range 0e6; SD 2) months; three branches were treated early and 10 later during follow up (Table 3) . Primary patency at 12, 24, 36, and 48 months was 94%, 94%, 93% and 93% respectively, and secondary patency 97%, 97%, 96%, and 96% respectively (Fig. 5A) months was 93%, 90%, 90%, and 90% (Fig. 5B) . Survival was not related to the type of aortic aneurysm treated (PRAA vs. TAAA) (p ¼ .077) but to the type of repair (elective vs. emergent) (p ¼ .003). One patient (4%, 1/28) died after reintervention (irreversible shock after an iliac artery disruption). During the follow up, 19 patients died (2 early and 17 late deaths). Of these 17 late deaths, five were directly related to the initial CPGeaortic stent graft procedure or a re-intervention.
The risk factor multivariate analysis for CPG failure showed a higher mortality (p ¼ .001) and re-intervention rate (p ¼ .01) in patients treated non-electively; a higher mortality rate in patients treated with multiple (3e4) CPGs (p ¼ .03); a higher re-intervention rate in highly stenosed or short CPGs (p ¼ .02); and a higher CPG occlusion (p ¼ .004) and re-intervention rate (p ¼ .005) in stenosed or small target vessels. There were associations with reinterventions for multiple (3e4) CPGs (p ¼ .06); with mortality for combined CPGs (p ¼ .06); and with CPG occlusion for highly stenosed or short CPGs (p ¼ .006) ( Table 4) .
DISCUSSION
Studies reporting the mid-and longer-term outcomes of chimney and/or periscope grafts used in reno-visceral vessels are rare and identification of risk factors for chimney and/or periscope graft failure are lacking. 20 As reported recently by the multicenter PERICLES registry, the results at 17.1 months from 517 patients treated by CPGs were similar to those of F/BEVAR. However, in this registry different devices (bare metal, covered, self expandable, or balloon expandable) have been used in reno-visceral vessels and no risk factor analysis for CPG failure was performed. 21 Based on the VORTEC experience using the Viabahn for sutureless anastomoses in reno-visceral vessels, 22e24 it was felt that felt that the Viabahn device would be ideal for CPG construction and therefore it was used exclusively for the parallel graft(s) in reno-visceral vessels. The intuition was confirmed in the actual series of 100 patients followed for a mean period of 28 months by absence of material failure and the high primary patency rate (93%) in the 16 patients followed >4 years. Post-operatively, CPG occlusion was observed in only 5.8% branches; the risk factors were CPG collapse and/or too short CPGs, target vessel atherosclerosis or a diameter <4 mm. With regard to the aortic stent graft there was no difference in outcome, maybe because of the relatively small samples. Few experimental and clinical data support the use of one device (aortic stent graft or branch stent graft) over another, 3, 9, 18, 25 and long-term results with different types of CPG devices (self expandable or balloon expandable) are needed. 26 The Viabahn is preferred for CPG construction because of its low profile, flexibility, and heparin coating. The excellent results, also in patients with long-term follow up, support this choice. In addition, the Viabahn X-ray visibility may increase with primary Wallstent relining. 10 This tool was employed increasingly in the later procedures, especially in cases of multiple CPGs. Finally, the 4 year cumulative patency rate of aortic branches preserved with CPGs is equivalent to those reported after B/FEVAR treatment for similar aortic pathologies (96% vs. 88.6%).
27e29 In this study, to fit the patient anatomy, different stent graft manufacturers were combined and used concurrently with no differences. This approach has been used with caution, and no drawbacks have been observed to date.
Endoleaks are regarded as a major concern 9 and represent a potential cause of aneurysm rupture. 26, 30 The policy to perform very sensitive CTA (arterial and venous phases) early post-operatively might explain the 23% endoleak incidence. However, this high rate must be tempered by the lack of persistence or clinical adverse consequences if endoleaks are addressed appropriately. When the endoleak did not seal spontaneously, it was eliminated by coilembolization or endograft extension, which showed durable effects over time. Persisting low flow Type I endoleaks did not result in aneurysm enlargement. Overall and despite these endoleaks, aneurysm diameter remained stable or decreased in 96% of patients, which compares favorably with the findings described after FEVAR (92e97%). 29, 31, 32 Moreover, when compared with data from Schanzer et al., 33 sac enlargement was less in the current series. It can be argued that this enlargement was related not only to a lower endoleak incidence (32 vs. 23%), but also to aggressive endoleak treatment based on adherence to a stricter follow up protocol.
Clinical outcomes of the mid-and longer-term experience of parallel graft techniques are consistent with 2% peri- 29, 36 These survival outcomes of both CPGs and F/BEVAR compare favorably with randomized control trials reporting on infrarenal AAA treatment, such as the EVAR 37 and OVER 38 trial using the older generation devices. Also the more recent cardiovascular medical support can play a role in survival outcome. 39 General anesthesia was employed more frequently in multiple CPGs and local anesthesia for less complex procedures. Patients treated for TAAAs required significantly longer ICU stays and showed less aneurysm shrinkage than patients treated for PRAAs. Moreover, in this group of patients, CPG outcomes seemed far better than those of similar lesions treated by open aortic surgery. 40 During follow up, patient survival after non-elective procedures and procedures requiring more than two CPGs was worse than after elective procedures with one or two CPGs. Patients requiring elective treatment with only one or two CPGs clearly had the best outcomes. However, the higher risk and challenging nature of patients requiring more complex procedures would seem to justify the CPG techniques in these patients as well.
This study has some limitations. First, there is no contemporary (institutional) clinical comparison with FEVAR or open repair. The main reason for this is that the actual study focus was on outcomes and risk factors for CPG complications, especially when the Viabahn branch grafts were used. As the Viabahn device is generally not used in FEVAR procedures, comparisons might have yielded confusing results of limited value. A second limitation of the study is that it included the learning curve(s) with different skills and techniques developed during experience with CPGs. A third limitation is that the study included a mixed group of different aortic lesions and clinical conditions (elective and emergent). In fact, as experience progressed, the techniques were adapted and developed so the CPG option could be offered to most patients with AAAs and/or TAAAs involving reno-visceral branch arteries. Because of this, and because major differences in constructing CPGs were not identified in these different anatomical and clinical circumstances, the group as a whole was reviewed to obtain sufficient numbers of patients to enable the authors to identify risk factors for CPG complications. Nevertheless, the results may not apply to CPG grafts constructed with different components or configurations. However the PERICLES registry results suggests that this may not be a limitation. 21 In conclusion, this experience in 100 patients treated with self expanding CPGs shows promising and durable midand longer-term term results (>4 years). Diseased native vessels, highly stenosed, or short CPGs and multiple (3e4) CPGs were significant risk factors for CPG failure. Nonelective CPG and multiple (3e4) CPGs were significant risk factors for death. Although the data suggest that the parallel graft methods for reno-vascular revascularization with complex AAAs may be equivalent to open surgery or FEVAR, more widespread experience and direct comparisons will be required to confirm this. The potential advantages of CPG techniques (off the shelf, versatility, generally immediate availability and low-profile devices) are obvious; however, the best indications for CPGs remain to be clarified. However, even at present, the wider use of such parallel grafting techniques, using the Viabahn, seems to be justified in situations in which F/BEVAR is not available and patients are at high risk for open surgical repair.
